Mark Paquin

Feature

Reducing Lead Apron Wear Time and Radiation Exposure with Remote-Controlled PCI: The Corindus CorPath

06/19/2008

David F. Kong , MD, AM, DMT;

PCI Evolves, Bringing New Problems for Operators PCI has evolved significantly during the last quarter century. According to a market report prepared by Morgan Stanley, the number of global PCI procedures is expected to exceed 2.6 million...

PCI Evolves, Bringing New Problems for Operators PCI has evolved significantly during the last quarter century. According to a market report prepared by Morgan Stanley, the number of global PCI procedures is expected to exceed 2.6 million...

PCI Evolves, Bringing New...

06/19/2008

Cath Lab Digest

The Cleveland Regional Medical Center: Experience with the Neptune Pad

06/19/2008

Daniel P. Link , MD;

Closure Devices and the Cath Lab of the 21st Century It has been close to a decade since the first vascular hemostasis device was approved by the FDA for commercial use. The adoption and use of closure devices following catheterization and...

Closure Devices and the Cath Lab of the 21st Century It has been close to a decade since the first vascular hemostasis device was approved by the FDA for commercial use. The adoption and use of closure devices following catheterization and...

Closure Devices and the Cath Lab...

06/19/2008

Cath Lab Digest

The Sideguard Ostium Protection Device: The next generation in bifurcation stenting

06/19/2008

Nearly 20 percent of all percutaneous coronary interventions (PCI) are performed at a bifurcation. Moreover, bifurcation and ostial lesions remain one of the more challenging coronary interventions faced by interventional cardiologists in our...

Nearly 20 percent of all percutaneous coronary interventions (PCI) are performed at a bifurcation. Moreover, bifurcation and ostial lesions remain one of the more challenging coronary interventions faced by interventional cardiologists in our...

Nearly 20 percent of all...

06/19/2008

Cath Lab Digest

Reducing Lead Apron Wear Time and Radiation Exposure with Remote-Controlled PCI: The Corindus CorPath

06/19/2008

David F. Kong , MD, AM, DMT;

PCI Evolves, Bringing New Problems for Operators PCI has evolved significantly during the last quarter century. According to a market report prepared by Morgan Stanley, the number of global PCI procedures is expected to exceed 2.6 million...

PCI Evolves, Bringing New Problems for Operators PCI has evolved significantly during the last quarter century. According to a market report prepared by Morgan Stanley, the number of global PCI procedures is expected to exceed 2.6 million...

PCI Evolves, Bringing New...

06/19/2008

Cath Lab Digest

Feature

The Cleveland Regional Medical Center: Experience with the Neptune Pad

06/19/2008

Daniel P. Link , MD;

Closure Devices and the Cath Lab of the 21st Century It has been close to a decade since the first vascular hemostasis device was approved by the FDA for commercial use. The adoption and use of closure devices following catheterization and...

Closure Devices and the Cath Lab of the 21st Century It has been close to a decade since the first vascular hemostasis device was approved by the FDA for commercial use. The adoption and use of closure devices following catheterization and...

Closure Devices and the Cath Lab...

06/19/2008

Cath Lab Digest

Feature

The Sideguard Ostium Protection Device: The next generation in bifurcation stenting

06/19/2008

Nearly 20 percent of all percutaneous coronary interventions (PCI) are performed at a bifurcation. Moreover, bifurcation and ostial lesions remain one of the more challenging coronary interventions faced by interventional cardiologists in our...

Nearly 20 percent of all percutaneous coronary interventions (PCI) are performed at a bifurcation. Moreover, bifurcation and ostial lesions remain one of the more challenging coronary interventions faced by interventional cardiologists in our...

Nearly 20 percent of all...

06/19/2008

Cath Lab Digest

Featured CME Course

Targeted Therapies for the Management of Chronic Lymphocytic Leukemia: Evaluating the Evidence to Optimize Patient Care and Outcomes

Upcoming Events

February 2 ⁠–⁠ February 5

February 7 ⁠–⁠ February 9

February 27 ⁠–⁠ March 1

DCLF

March 17 ⁠–⁠ March 19

March 22 ⁠–⁠ March 23

NP Institute

March 27 ⁠–⁠ March 30

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

April 30 ⁠–⁠ May 4

WoundCon

May 1 ⁠–⁠ May 3

See Full Calendar